Micafungin Hikma

Micafungin, the active ingredient in Micafungin Hikma, is an echinocandin presented as an intravenous formulation for infusion use. It treats invasive Candida infections and is used for prophylaxis in patients undergoing hematopoietic stem cell transplantation. GNH USA supplies Micafungin Hikma as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres, oncology centres and pharmacies worldwide.

Micafungin is an echinocandin antifungal that targets invasive Candida infections and related prophylaxis. - Invasive candidiasis: treatment of bloodstream and deep‑tissue Candida infections in adults. - Candida esophagitis: eradication of esophageal Candida lesions causing dysphagia. - Candida peritonitis: management of intra‑abdominal Candida infection in critically ill patients. - Candida febrile neutropenia: therapy for neutropenic patients with fever due to Candida. - Prophylaxis of Candida infections in hematopoietic stem cell transplantation: prevention of invasive candidiasis in transplant recipients.

Micafungin may cause a range of adverse reactions, from mild to severe.

Common Side Effects: - Infusion‑related reactions: flushing, chills, or rigors during administration. - Fever: transient elevations in body temperature. - Nausea or vomiting: gastrointestinal discomfort. - Headache: mild to moderate intensity. - Elevated liver enzymes: transient increases in ALT or AST. - Rash: mild skin erythema or pruritus.

Serious or Rare Side Effects: - Severe hepatic failure: marked liver enzyme elevation with jaundice. - Anaphylaxis: acute, life‑threatening allergic reaction. - Stevens‑Johnson syndrome or toxic epidermal necrolysis: severe skin detachment. - Acute renal failure: sudden loss of kidney function. - Severe hypotension: marked drop in blood pressure during infusion. - Eosinophilia: marked increase in eosinophil count.

Before initiating Micafungin, clinicians should consider several safety factors. - Renal function: monitor creatinine and adjust therapy in renal impairment. - Hepatic function: assess baseline liver enzymes and repeat monitoring during treatment. - Hypersensitivity: discontinue immediately if severe allergic reactions occur. - Drug interactions: review concomitant medications for potential pharmacokinetic effects. - Pregnancy and lactation: use only if potential benefit justifies potential risk to fetus or infant. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Micafungin can interact with several drug classes, requiring careful management.

Major Interactions (Avoid): - Strong CYP3A4 inducers (e.g., rifampin): may markedly reduce micafungin exposure. - Strong CYP3A4 inhibitors (e.g., ketoconazole): may increase micafungin plasma levels. - Co‑administration with other echinocandins: risk of additive toxicity.

Moderate Interactions (Monitor Closely): - Azole antifungals (e.g., fluconazole): may raise micafungin concentrations. - Rifampin: may lower micafungin levels, requiring dose adjustment. - Immunosuppressants (e.g., tacrolimus, cyclosporine): monitor drug levels for possible alteration.